Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MER1 repeat containing imprinted transcript 1 (MIMT1) is a long intergenic non-coding RNA gene located on chromosome 19 in humans[1][7]. MIMT1 undergoes alternative splicing, resulting in at least two transcript variants, and does not encode a protein[1][5]. The gene is imprinted and may regulate the expression of neighboring genes, notably PEG3 and USP29, through a bidirectional promoter mechanism[5]. Microdeletions that disrupt MIMT1 expression are associated with developmental abnormalities in cattle, specifically stillbirth and compromised placental function, likely due to altered imprinting and gene regulation[5]. In humans, MIMT1 is significantly down-regulated in colorectal cancer, suggesting a potential role as a tumor suppressor lncRNA, though its mechanistic functions remain to be confirmed[2]. As a lncRNA, MIMT1 participates in transcriptional and epigenetic regulation but is currently not regarded as a standard therapeutic target, nor does it have known interacting drugs or established mechanisms for pharmacological intervention[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MER1 repeat containing imprinted transcript 1 (MIMT1).